|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.0000 - 0.0000|
|52 Week Range|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
OTCQX: ELLXF), has expanded its EU operations with key personnel hires and offices in the Netherlands, Spain, and the United Kingdom. The appointments are accompanied by a new go-to-market strategy and key initiatives including the launch of new e-commerce capabilities, sales hubs, with 12 full-time sales and marketing employees, in the Netherlands, Spain, and the United Kingdom aimed at capturing the European cannabis market opportunity, which analysts expect will be worth more than $130 billion in annual sales by 2028 (in today’s dollars).
SAN FRANCISCO, Feb. 05, 2019 -- Fincom Investment Partners discusses Elixinol Global Ltd.'s (EXL:ASX; ELLXF:OTCQX) Q4 earnings, and the hemp/CBD field. Company mentioned:.
Leading global hemp CBD company Elixinol, has announced its entry into the New Zealand marketplace, offering its comprehensive range of cannabidiol (CBD) products to the NZ public on a prescription basis via the elixinol.com website. OTCQX: ELLXF) and has launched in New Zealand following the December 2018 passage of New Zealand’s Misuse of Drugs (Medicinal Cannabis) Amendment Act.
The announcement comes on the heels of the December 2018 passage of New Zealand’s Misuse of Drugs (Medicinal Cannabis) Amendment Act which classifies CBD, with low levels of THC as prescription medicine and removes CBD as a Class B1 controlled drug. Individual patients may now import up to a 3-month supply of CBD products, provided those products meet prescription medicine guidelines. Medicinal practitioners, pharmacies may also import and sell CBD products as can individuals or companies holding a license to sell medicines in New Zealand.
OTC: ELLXF), announces Joy Beckerman’s appointment to Elixinol’s team starting January 1, 2019. In Beckerman’s role as Regulatory Officer and Industry Liaison, she will advise Elixinol’s executive team on the industry’s changes and ensure Elixinol’s practices continue to meet or exceed the requirements of hemp’s dynamic regulatory framework following the 2018 Farm Bill which federally legalized hemp.
Paul Benhaim launched one of the most successful CBD companies in the world, but he's putting some of the riches from that venture back into hemp plastics — a bygone dream made possible by the farm bill.
SAN FRANCISCO, Dec. 18, 2018 -- The U.S. Congress passed the 2018 Farm Bill that legalizes hemp; the bill is expected to be signed by the President soon. Against this backdrop,.
The 2018 Farm Bill was passed by the Senate on Tuesday by a vote of 87-13. The next move is that the legislation heads to the House for a vote -- and then if it passes there, it goes to President Trump to be signed into law. The impact of this legislation on the cannabis industry is enormous.
DENVER, Dec. 11, 2018 -- US-based Elixinol announces the distribution of its first globally available, all-natural, hemp-based skin care and hair care line, Sativa. The 8.
NEW YORK, NY / ACCESSWIRE / December 11, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Elixinol Global Limited (ELLXF), a global presence in the cannabis industry including hemp-derived CBD dietary supplements, food and wellness products, as well as the cultivation and manufacture of medicinal cannabis products. The Company is closely monitoring ongoing 2018 Farm Bill legislative changes in the US which, if passed will strengthen the Elixinol USA business considerably and open up its ability to trade nationally and accelerate growth. The management expects growth in the Hemp Foods Australia business to be supported by launches of the company's own finished food products and penetration in the cosmetics segment through its SATIVA Skincare range.
As the industry impatiently awaits passage of the 2018 Farm Bill and pending removal of hemp from the Controlled Substances Act, companies are quickly moving to position themselves as leading suppliers of hemp-based CBD products, and investors are all too happy to help foot the bill. Two companies that have been particularly aggressive in their pursuit of the hemp-based CBD market have been Elixinol Global Ltd. (OTCQX: ELLXF) and MariMed, Inc. (OTCQB:MRMD). Shares for the IPO were sold at $1.00 AUD per share ($0.73 USD), but the stock quickly climbed to $1.82 AUD ($1.32 USD) within the first week of trading.
NEW YORK , Sept. 18, 2018 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced Elixinol Global Limited (ASX: EXL; ...
Catapult Group International is one of many stocks the market is bullish on. Its expected double-digit top-line and bottom-line growth exceeds its peers, and its financially stable position lessens theRead More...